Literature DB >> 9683129

Recurrent pyogenic cholangitis.

H W Harris1, Z L Kumwenda, S M Sheen-Chen, A Shah, W P Schecter.   

Abstract

BACKGROUND: Recurrent pyogenic cholangitis is a complex biliary tract disease characterized by intrahepatic pigment stones, endemic to Southeast Asia and seen with increasing frequency in the United States. The purpose of this study was to review the management of this disorder in a county hospital.
METHODS: A retrospective review of 45 patients with recurrent pyogenic cholangitis evaluated between 1984 and 1995. The clinical and surgical management of patients with localized versus bilateral hepatolithiasis were compared.
RESULTS: The prevalence of recurrent pyogenic cholangitis at our hospital has more than doubled since 1983. Fourteen of 45 patients (31%) had bilateral disease and required more abdominal computed tomography scans (P < 0.01), percutaneous cholangiograms (P < 0.05), endoscopies (P < 0.01), clinic visits (P < 0.05), and hospital admissions (P < 0.02) as compared with patients with localized disease.
CONCLUSIONS: The effective treatment of recurrent pyogenic cholangitis requires definition of the patients' intrahepatic distribution of disease, prior to surgical intervention, and the coordinated efforts of gastroenterologists, radiologists, and surgeons.

Entities:  

Mesh:

Year:  1998        PMID: 9683129     DOI: 10.1016/s0002-9610(98)00095-6

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  14 in total

1.  Surgical Education and Self-assessment Program (SESAP). Recurrent pyogenic cholangitis.

Authors: 
Journal:  Can J Surg       Date:  2004-04       Impact factor: 2.089

2.  Hepatectomy with primary closure of common bile duct for hepatolithiasis combined with choledocholithiasis.

Authors:  Chang-Ku Jia; Jie Weng; You-Ke Chen; Qing-Zhuang Yang; Yu Fu; Qi-Fan Qin; Wei-Ming Yu
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

3.  Outcomes of hepatectomy for hepatolithiasis.

Authors:  Tung-Yen Lee; Yao-Li Chen; Hung-Chi Chang; Chien-Pin Chan; Shou-Jen Kuo
Journal:  World J Surg       Date:  2007-03       Impact factor: 3.352

4.  Recurrent pyogenic cholangitis in a white woman.

Authors:  Simon Bergman; Antonio Di Carlo; Prosanto Chaudhury; Carl Blum; Ayoub Nahal; Peter Metrakos
Journal:  Can J Surg       Date:  2007-10-10       Impact factor: 2.089

5.  Oriental cholangiohepatitis masquerading as cholangiocarcinoma: A rare presentation that surgeons need to know.

Authors:  Smit Singla; Anne H Warner; Ashokkumar Jain; Rebecca M Thomas; Andreas Karachristos
Journal:  Int J Surg Case Rep       Date:  2012-03-16

6.  Recurrent pyogenic cholangitis with hepatolithiasis--the role of surgical therapy in North America.

Authors:  Wigdan Al-Sukhni; Steven Gallinger; Ariella Pratzer; Alice Wei; C S Ho; Paul Kortan; Bryce R Taylor; David R Grant; Ian McGilvray; Mark S Cattral; Bernard Langer; Paul D Greig
Journal:  J Gastrointest Surg       Date:  2007-11-13       Impact factor: 3.452

7.  Robotic-assisted laparoscopic surgery for complex hepatolithiasis: a propensity score matching analysis.

Authors:  Jie Shu; Xiao-Jun Wang; Jian-Wei Li; Ping Bie; Jian Chen; Shu-Guo Zheng
Journal:  Surg Endosc       Date:  2018-10-22       Impact factor: 4.584

8.  Outcome of surgery for recurrent pyogenic cholangitis: a single center experience.

Authors:  Sukanta Ray; Sumit Sanyal; Kshaunish Das; Ranajoy Ghosh; Somak Das; Sujan Khamrui; Avik Sarkar; Gautam Chattopadhyyay
Journal:  HPB (Oxford)       Date:  2016-06-28       Impact factor: 3.647

Review 9.  Significance of controlling chronic proliferative cholangitis in the treatment of hepatolithiasis.

Authors:  Fu Yu Li; Nan Sheng Cheng; Hui Mao; Li Sheng Jiang; Jing Qiu Cheng; Quan Sheng Li; Sanjay Munireddy
Journal:  World J Surg       Date:  2009-10       Impact factor: 3.352

10.  Recurrent pyogenic cholangitis treated by left hepatectomy.

Authors:  Sukanta Ray
Journal:  Indian J Surg       Date:  2011-04-15       Impact factor: 0.656

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.